Focused On-demand Library for Runt-related transcription factor 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q13950

UPID:

RUNX2_HUMAN

Alternative names:

Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; Oncogene AML-3; Osteoblast-specific transcription factor 2; Polyomavirus enhancer-binding protein 2 alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit

Alternative UPACC:

Q13950; O14614; O14615; O95181

Background:

Runt-related transcription factor 2 (RUNX2) is a pivotal transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. It plays a crucial role in the maturation of osteoblasts and is essential for both intramembranous and endochondral ossification. RUNX2's ability to bind to various enhancers and promoters facilitates the transcription of genes critical for bone development and homeostasis.

Therapeutic significance:

RUNX2's involvement in diseases such as Cleidocranial dysplasia 1 and Metaphyseal dysplasia with maxillary hypoplasia underscores its therapeutic significance. Understanding the role of RUNX2 could open doors to potential therapeutic strategies for these skeletal disorders, highlighting the importance of targeted research in uncovering novel treatments.